

# First task

Akvilė Višniauskaitė ir Ieva Pudžiuvėlytė

3/11/2022

## Introduction

This work will present data analysis from a research that studied the enhancer's at *IGF2* differential methylation association with abnormal dopamine synthesis in major psychosis (Pai et al., 2019).

Our samples were taken from the prefrontal cortex isolated neurons in schizophrenia and bipolar disorder.

Study analysed data from individuals diagnosed with schizophrenia, bipolar disorder and controls (29, 26 and 27 individuals, respectively). In the analysis study controlled for age, sex, post-mortem interval, genetic ancestry (determined by genotyping the same individuals).

## Experiment design

The experiment design was multi-omics study with 55 cases (with schizophrenia or bipolar disorder) and 27 controls.

## Objective of the research

According to authors, schizophrenia and bipolar disorder have got characteristic of periods of psychosis. The main objective of the research was to gather epigenomic profiling data to get a more accurate model of neuronal dysregulation in diseases with periods of psychosis.

## Biological targets of the research

Researchers intended to look for specific patterns of DNA methylation in isolated neurons from the frontal cortex of individuals that had diseases.

- IGF2 - insulin growth factor 2 protein
- *IGF2* - IGF2 gene
- *Igf2* - enhancer of *IGF2*
- TH - tyrosine hydroxylase protein
- dopamine - a neuromodulatory molecule
- psychosis - an abnormal condition of the mind that results in difficulties determining what is real and what is not real

## Results received

Authors found a strong association between methylation of *Igf2* and TH synthesis. TH is the bottleneck enzyme that is responsible for dopamine synthesis. If enhancer *Igf2* is hypomethylated, levels of TH are higher, which determines the higher production of dopamine. Apparently, dopamine is responsible for psychosis in the mental disorders of interest.

## Additional information

Schizophrenia and bipolar disorder patients are consistently hypomethylated at *IGF2* locus when compared to controls. This locus remained significantly hypomethylated even after accounting lifestyle-related variables of smoking and anti-psychotic use.

The reaction chain of interest of the research (upward arrows show elevated expression or synthesis of the protein, product, or effect):

Hypomethylation of *Igf2*  $\rightarrow$   $\uparrow$  IGF2  $\rightarrow$   $\uparrow$  TH  $\rightarrow$   $\uparrow$  dopamine  $\rightarrow$   $\uparrow$  psychosis

## Data preparation

```
BiocManager::install("IlluminaHumanMethylationEPICanno.ilm10b4.hg19")
library(IlluminaHumanMethylationEPICanno.ilm10b4.hg19)
```

Sample keys heading is made of the following columns names:

- *id* - an identifier of the sample
- *sentrix\_id* - Illumina's Sentrix BeadChip identifier (13 unique values) (National Institutes of Health, n.d.)
- *sentrix\_row* - row number in the Sentrix array
- *sentrix\_col* - column number in the Sentrix array
- *basename* - sample identifier in the research (joined values in a format: `[id]_[sentrix_id]_R0[sentrix_row]C0[sentrix_id]`)
- *tissue\_bank\_id* - an identifying number of the tissue bank from which the sample was taken
- *tissue\_bank* - the literal identifier of the tissue bank
- *tissue* - a tissue type from which the sample was taken
- *cell\_type* - a cell type found in the sample
- *donor* - an integer number that identifies the donor of the sample (82 unique values)
- *pmi* - a post-mortem interval (**time units??????????**), unknown values were labeled as NA
- *race* - race of the donor (white, black, hispanic, or unknown (NA))
- *sex* - gender of the donor
- *diagnosis* - an experimental group of the donor (bipolar, schizophrenia, or control)
- *age* - age of the donor (years)

As it was noted in the article, there were 100 records in the sample keys dataset.

## Calculating detection p-values

Getting detection p-value for each score of DNA modification. These p-values determine whether the measured intensity can be distinguished from the background.

All values that have got p-value higher than 0.01 are considered as bad and all samples that have more than 1% of bad detection p-values should be removed.

Although, in our data, none of the samples had more than 1% of bad values, therefore no sample was removed.

## Predicting sample sex

This stage estimates sample sex based on methylation data.

Number of females and males after estimation matched original data (25 female and 75 male).

Converted ‘M’ and ‘F’ notation to ‘male’ and ‘female’.

No mismatches between real and estimated sex were found.

## Data normalisation

According to the documentation of *minfi* package (Fortin & Hansen, n.d.), *preprocessFunnorm()* function is recommended for known large-scale differences (for example, cancer/normal) or between-tissue studies. Our chosen data spans only over one cell type of one tissue, therefore it was decided to opt for different normalisation methods.

Authors (Pai et al., 2019) noted that they used noob normalisation followed by the quantile one. Quantile normalisation performs processing of Type I and Type II array design differences. Whereas, *preprocessIllumina()* normalisation has only background subtraction and control normalisation implemented. Therefore, we decided to choose *preprocessSWAN()* normalisation, since this method performs within-array normalisation correction for technical differences between Type I and Type II array designs.

## Filtering position data by detection p-values

There were 5835 positions found that had p-value higher than 0.01 in 1% of the samples. These positions were removed from the dataset. After this procedure, we have 861001 positions in each sample.

## Load data for the 6th point of data preparation

## Quality control

We checked standard deviations within each group.

Samples that were outliers by more than 2 standard deviations within cases

82\_R01C01 74\_R07C01

## References

- Fortin, J.-P., & Hansen, K. D. (n.d.). Analysis of 450k data using minfi. *Dim*, 485512, 6.
- National Institutes of Health, N. C. I. at the. (n.d.). *Sentrix® BeadChip and BeadArray technology (illumina, inc.) / innovative molecular analysis technologies (IMAT)*. <https://imat.cancer.gov/about-imat/outputs-and-achievements/individual-technologies-and-platforms/sentrix%C2%AE-beadchip-and>
- Pai, S., Li, P., Killinger, B., Marshall, L., Jia, P., Liao, J., Petronis, A., Szabó, P. E., & Labrie, V. (2019). Differential methylation of enhancer at IGF2 is associated with abnormal dopamine synthesis in major psychosis. *Nature Communications*, 10(1), 1–12.